Evidence map›Paper›PMID 40552131›Full record

ArticleBlood neoplasia2024

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.

Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, Alison Griffin, Rakin Chowdhury, Ross Salvaris, Amanda Goh, Harrison Black, Tsz Hung Tong, Callum Birks and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Joshua W D TobinDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Venkata A ChikatamarlaSchool of Medicine, The University of Queensland, Brisbane, Australia.
Marko MaticDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Alison GriffinStatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Rakin ChowdhuryDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Ross SalvarisDepartment of Haematology, Monash Health and Monash University, Melbourne, VIC, Australia.
Amanda GohDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Harrison BlackDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Tsz Hung TongDepartment of Haematology, Gold Coast University Hospital, Gold Coast, QLD, Australia.
Callum BirksDepartment of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Sanjiv JainHaematology Unit, ACT Pathology, Canberra Health Services, Canberra, Australia.
Elizabeth GoodallDepartment of Haematology, Austin Health, Melbourne, VIC, Australia.
Shreerang SirdesaiDepartment of Haematology, Barwon Health, University Hospital Geelong, Geelong, VIC, Australia.
Thomas TrevisDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Elizabeth SteinepreisDepartment of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
Yiyang ChenDepartment of Haematology, Flinders Medical Centre, Adelaide, SA, Australia.
Li LiDepartment of Haematology, Ochsner Clinic Foundation, New Orleans, LA.
Glenn BroadbyDepartment of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia.
Naadir GuttaDepartment of Haematology, Mater Hospital, Brisbane, QLD, Australia.
Kirk MorrisDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Tara CochraneDepartment of Haematology, Gold Coast University Hospital, Gold Coast, QLD, Australia.
Judith TrotmanDepartment of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Dipti TalaulikarHaematology Unit, ACT Pathology, Canberra Health Services, Canberra, Australia.
Jake ShorttDepartment of Haematology, Monash Health and Monash University, Melbourne, VIC, Australia.
Georgina HodgesDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Eliza A HawkesDepartment of Haematology, Austin Health, Melbourne, VIC, Australia.
Chan Y CheahDepartment of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Allison BarracloughDepartment of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
Kate ManosDepartment of Haematology, Flinders Medical Centre, Adelaide, SA, Australia.
Anna JohnstonDepartment of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia.
Jane RoyleDepartment of Haematology, Townsville Hospital, Townsville, QLD, Australia.
Patrizia MondelloDivision of Haematology, Mayo Clinic, Rochester, MN.
Stephen M AnsellDivision of Haematology, Mayo Clinic, Rochester, MN.
Greg HapgoodDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progression of follicular lymphoma (FL) or transformation (TFL) within 24 months of immunochemotherapy (ICT) represent high-risk defining events (HRDE) with poor overall survival (OS). We examined baseline clinical characteristics, imaging, and outcomes for patients experiencing HRDE with newly diagnosed FL requiring ICT. HRDE groups were: relapse or progression of FL within 24 months (FL24), early TFL (transformation <24 months of ICT), late TFL (transformation >24 months of ICT).433 patients were categorized as reference FL (Ref FL), n = 352 (no HRDE); FL24, n = 43; early TFL, n = 29; late TFL, n = 9. Chemotherapy included bendamustine (63%), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) (27%), or CVP (cyclophosphamide, vincristine, prednisone) (10%); 85% received rituximab/15% obinutuzumab and 48% received maintenance therapy. Compared with Ref FL group, OS from HRDE was inferior for FL24 (hazard ratio [HR], 3.93; 95% confidence interval [CI], 2.14-7.23), early TFL (HR, 8.16; 95% CI, 4.38-15.2), and late TFL (HR, 8.23; 95% CI, 3.18-21.25). OS from HRDE was inferior for early TFL compared with FL24 (HR, 2.08; 95% CI, 1.02-4.21). In multivariable analysis, performance status, lactate dehydrogenase, beta-2-microglobulin and grade 3A were associated with early TFL. Clinical characteristics did not differentiate early TFL from FL24. Maximum standardized uptake value was higher in early TFL but not FL24 compared to Ref FL. Early TFL and FL24 represent different HRDEs and are associated with inferior OS. Distinguishing early TFL from FL24 is important for biomarker development, management and to develop and interpret trials in this area of unmet need.

Identifiers

PMID40552131
PMCPMC12182845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.